Shortage of hyoscine hydrobromide 400 and 600 micrograms/ml solution for injection

· London and South East Regional Medicines Information Service

There is a shortage of both strengths due to problems obtaining the active ingredient to manufacture the injection. This affects all suppliers and is expected to last for several months. This memo discusses alternative treatment options in the interim.

NOTE: Although the shortage has resolved, the memo has been retained, as this product is subject to intermittent shortages. The contents of the memo, however, have not been updated since the publication date.


Acute CareHyoscine hydrobromidePrimary CareShortages and discontinuations